The present study demonstrates that the novel platelet-sparing BCLXL protac degrader, DT2216, selectively degrades BCLXL in all myeloma cells tested but only kills cells highly primed for BCLXL. The gene discussed is BCL2L1; the disease is plasma cell myeloma.